Chicago—Unprecedented response rates were achieved with a novel antibody drug conjugate for relapsed or refractory small cell lung cancer (SCLC), according to a Phase I dose-ranging study presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).
The agent, rovalpituzumab tesirine (Rova-T, AbbVie), targets the δ-like 3 (DLL3) protein. For those with this target, which represented the majority of patients tested, the response rates observed during the